vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and V F CORP (VFC). Click either name above to swap in a different company.
V F CORP is the larger business by last-quarter revenue ($2.9B vs $2.8B, roughly 1.0× Bausch Health Companies Inc.). V F CORP runs the higher net margin — 10.5% vs -3.7%, a 14.1% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 1.5%). V F CORP produced more free cash flow last quarter ($977.9M vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 10.1%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
The F. W. Woolworth Company was a retail company and one of the pioneers of the five-and-dime store. It was among the most successful American and international five-and-dime businesses, setting trends and creating the modern retail model that stores worldwide follow today.
BHC vs VFC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.9B |
| Net Profit | $-103.0M | $300.8M |
| Gross Margin | — | 56.6% |
| Operating Margin | 17.0% | 10.1% |
| Net Margin | -3.7% | 10.5% |
| Revenue YoY | 9.3% | 1.5% |
| Net Profit YoY | -205.1% | 79.3% |
| EPS (diluted) | $-0.30 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.9B | ||
| Q3 25 | $2.7B | $2.8B | ||
| Q2 25 | $2.5B | $1.8B | ||
| Q1 25 | $2.3B | $2.0B | ||
| Q4 24 | $2.6B | $2.8B | ||
| Q3 24 | $2.5B | $2.8B | ||
| Q2 24 | $2.4B | $1.9B | ||
| Q1 24 | $2.2B | $2.4B |
| Q4 25 | $-103.0M | $300.8M | ||
| Q3 25 | $179.0M | $189.8M | ||
| Q2 25 | $148.0M | $-116.4M | ||
| Q1 25 | $-58.0M | $-150.8M | ||
| Q4 24 | $98.0M | $167.8M | ||
| Q3 24 | $-85.0M | $52.2M | ||
| Q2 24 | $10.0M | $-258.9M | ||
| Q1 24 | $-64.0M | $-418.3M |
| Q4 25 | — | 56.6% | ||
| Q3 25 | — | 52.2% | ||
| Q2 25 | — | 53.9% | ||
| Q1 25 | — | 52.7% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 52.2% | ||
| Q2 24 | — | 52.0% | ||
| Q1 24 | — | 48.4% |
| Q4 25 | 17.0% | 10.1% | ||
| Q3 25 | 23.1% | 11.2% | ||
| Q2 25 | 17.5% | -4.9% | ||
| Q1 25 | 12.2% | 2.2% | ||
| Q4 24 | 21.8% | 8.0% | ||
| Q3 24 | 12.7% | 9.9% | ||
| Q2 24 | 16.2% | -12.6% | ||
| Q1 24 | 13.1% | -15.0% |
| Q4 25 | -3.7% | 10.5% | ||
| Q3 25 | 6.7% | 6.8% | ||
| Q2 25 | 5.8% | -6.6% | ||
| Q1 25 | -2.6% | -7.5% | ||
| Q4 24 | 3.8% | 5.9% | ||
| Q3 24 | -3.4% | 1.9% | ||
| Q2 24 | 0.4% | -13.6% | ||
| Q1 24 | -3.0% | -17.6% |
| Q4 25 | $-0.30 | $0.76 | ||
| Q3 25 | $0.48 | $0.48 | ||
| Q2 25 | $0.40 | $-0.30 | ||
| Q1 25 | $-0.16 | $-0.37 | ||
| Q4 24 | $0.24 | $0.43 | ||
| Q3 24 | $-0.23 | $0.13 | ||
| Q2 24 | $0.03 | $-0.67 | ||
| Q1 24 | $-0.17 | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $1.5B |
| Total DebtLower is stronger | $20.8B | $3.6B |
| Stockholders' EquityBook value | $-554.0M | $1.8B |
| Total Assets | $26.4B | $10.4B |
| Debt / EquityLower = less leverage | — | 1.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.3B | $419.1M | ||
| Q2 25 | $1.7B | $642.4M | ||
| Q1 25 | $1.1B | $429.4M | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $719.0M | $492.2M | ||
| Q2 24 | $595.0M | $637.4M | ||
| Q1 24 | $733.0M | $674.6M |
| Q4 25 | $20.8B | $3.6B | ||
| Q3 25 | $21.0B | $3.5B | ||
| Q2 25 | $21.7B | $3.6B | ||
| Q1 25 | $21.5B | $3.4B | ||
| Q4 24 | $21.6B | $3.9B | ||
| Q3 24 | $21.5B | $4.0B | ||
| Q2 24 | $21.7B | $3.9B | ||
| Q1 24 | $22.1B | $4.7B |
| Q4 25 | $-554.0M | $1.8B | ||
| Q3 25 | $-565.0M | $1.5B | ||
| Q2 25 | $-764.0M | $1.3B | ||
| Q1 25 | $-1.2B | $1.5B | ||
| Q4 24 | $-1.3B | $1.7B | ||
| Q3 24 | $-1.2B | $1.4B | ||
| Q2 24 | $-1.2B | $1.4B | ||
| Q1 24 | $-1.1B | $1.7B |
| Q4 25 | $26.4B | $10.4B | ||
| Q3 25 | $26.8B | $10.6B | ||
| Q2 25 | $27.3B | $10.2B | ||
| Q1 25 | $26.4B | $9.4B | ||
| Q4 24 | $26.5B | $10.6B | ||
| Q3 24 | $26.5B | $12.2B | ||
| Q2 24 | $26.5B | $11.5B | ||
| Q1 24 | $26.9B | $11.6B |
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 2.40× | ||
| Q2 25 | — | 2.76× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 2.86× | ||
| Q2 24 | — | 2.84× | ||
| Q1 24 | — | 2.84× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $1.0B |
| Free Cash FlowOCF − Capex | $403.0M | $977.9M |
| FCF MarginFCF / Revenue | 14.4% | 34.0% |
| Capex IntensityCapex / Revenue | 3.3% | 1.1% |
| Cash ConversionOCF / Net Profit | — | 3.36× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $357.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $1.0B | ||
| Q3 25 | $405.0M | $-227.0M | ||
| Q2 25 | $289.0M | $-145.5M | ||
| Q1 25 | $211.0M | $-171.1M | ||
| Q4 24 | $601.0M | $918.1M | ||
| Q3 24 | $405.0M | $-301.6M | ||
| Q2 24 | $380.0M | $19.8M | ||
| Q1 24 | $211.0M | — |
| Q4 25 | $403.0M | $977.9M | ||
| Q3 25 | $314.0M | $-253.5M | ||
| Q2 25 | $190.0M | $-173.7M | ||
| Q1 25 | $96.0M | $-193.0M | ||
| Q4 24 | $495.0M | $899.7M | ||
| Q3 24 | $334.0M | $-322.4M | ||
| Q2 24 | $302.0M | $-5.4M | ||
| Q1 24 | $129.0M | — |
| Q4 25 | 14.4% | 34.0% | ||
| Q3 25 | 11.7% | -9.0% | ||
| Q2 25 | 7.5% | -9.9% | ||
| Q1 25 | 4.2% | -9.6% | ||
| Q4 24 | 19.3% | 31.7% | ||
| Q3 24 | 13.3% | -11.7% | ||
| Q2 24 | 12.6% | -0.3% | ||
| Q1 24 | 6.0% | — |
| Q4 25 | 3.3% | 1.1% | ||
| Q3 25 | 3.4% | 0.9% | ||
| Q2 25 | 3.9% | 1.6% | ||
| Q1 25 | 5.1% | 1.1% | ||
| Q4 24 | 4.1% | 0.6% | ||
| Q3 24 | 2.8% | 0.8% | ||
| Q2 24 | 3.2% | 1.3% | ||
| Q1 24 | 3.8% | — |
| Q4 25 | — | 3.36× | ||
| Q3 25 | 2.26× | -1.20× | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | 5.47× | ||
| Q3 24 | — | -5.78× | ||
| Q2 24 | 38.00× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
VFC
| Outdoor | $1.9B | 67% |
| Sales Channel Through Intermediary | $813.4M | 28% |
| Other | $136.3M | 5% |
